体积 3, 问题 12 (2013)
评论文章
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
回顾：临床试验结果
Macrolide therapy in cystic fibrosis: new developments in clinical use
K Frayman,P Robinson
回顾：临床试验结果
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
评论文章
Surrogate end points: when should they be used?
Geert Molenberghs, Ariel Alonso Abad, Wim van der Elst, Tomasz Burzykowski, Marc Buyse
研究更新
Developing a consortium for ALS clinical research: the Canadian ALS Research Network
Lorne Zinman, Angela Genge,Denise A Figlewicz
回顾：临床试验结果
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
评论文章
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases
Loretta A Williams, Emre Yucel, Jorge E Cortes,Charles S Cleeland
